


Novel Targets Involved in Ferroptosis for Therapeutic Development in Oncology

Cumulus Oncology is developing **anti-cancer therapies** for clinical settings in areas of high unmet need, with the aim of developing improved outcomes for cancer patients. In particular, the company is interested in the identification of **specific molecular targets and biomarkers** associated with **ferroptosis**, which allow for the development of targeted therapies.



Approaches of Interest:

- **All cancers** are within scope
- Open to different modalities including **small molecules, biologics and mRNA therapeutics**, targeting any mechanism of ferroptosis
- Platforms that identify **ferroptosis targets** and platforms that help in **deconvoluting the mechanism involved in ferroptosis** are of high interest
- Research opportunities relating to **combination of ferroptosis-inducing agents with conventional cancer therapies**, such as chemotherapy and radiation are within scope
- Projects that have a **clear line of sight** will be prioritised

Out of Scope:

- Drug-repurposing, gene therapy and cell therapies

Developmental Stages of Interest:

- Basic research to preclinical studies is within scope
- Research with proof of concept will be prioritised
- *In vitro* validation, such as cancer cell line studies, and *in vivo* validation are both of interest






Submission Information

Submissions of one-page, 200–300-word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Ideally, submissions should also include a data summary. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **2nd April 2024 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk